S-2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole

When the downstream requirement is a generic immediate-release tablet containing pramipexole dihydrochloride monohydrate as the active moiety, the S-DATHB-derived API is dry-blended with microcrystalline cellulose NF (Avicel PH-102) and a crospovidone disintegrant. The API-to-filler ratio in a 0.25 mg base-equivalent tablet is fixed at 1:240 (w/w) to ensure a blend uniformity that meets USP <905> acceptance value (AV) below 15.0. A 0.5% magnesium stearate (vegetable grade, Ph. Eur.) lubricant addition is delayed until the final 3 minutes of blending to avoid over-lubrication, which would elevate disintegration time above the 15-minute threshold of the USP disintegration test. Direct compression is executed on a rotary tablet press (e.g., Fette 2090i) with 25 kN main compaction force, monitored by in-process hardness testing at 50–70 N. Die-wall friction is mitigated by a forced feeder paddle speed of 12 rpm. The finished tablet core complies with dissolution acceptance of Q=80% at 30 minutes in 0.05 M phosphate buffer pH 6.8, paddle at 50 rpm (USP <711> Apparatus 2). Terminal packaging in alu-alu cold-form blisters controls moisture ingress below 3.0% equilibrium relative humidity, as the dihydrochloride monohydrate deliquesces above 60% RH. Incompatibility is observed with solid dosage forms containing basic buffers: the free base can precipitate in the gut microenvironment if co-formulated with calcium carbonate in fixed-dose combinations.

How the S-Enantiomer Enters the Final API via Propionaldehyde Reductive Amination

Pramipexole dihydrochloride monohydrate API is produced by coupling (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with propionaldehyde under reductive conditions. The process is conducted within a cGMP framework aligned to FDA 21 CFR Part 211 and ICH Q7. The chiral diamine is charged into dichloromethane (dried over 4 Å molecular sieves) at a concentration of 0.5 M. Propionaldehyde is added in a 1.05-fold molar excess relative to the diamine to compensate for evaporative loss at the reactor condenser set to −5 °C. Sodium triacetoxyborohydride (NaBH(OAc)₃) is introduced portionwise as the reducing agent at a 1.5:1 molar ratio to substrate, maintaining the internal temperature at 20–25 °C by jacket cooling. The pH of the reaction mixture drifts from 5.5 to 6.2 over the 4-hour hold period; deviation above pH 7.0 triggers formation of dimeric by-products detectable by HPLC (C18 column, acetonitrile/0.1% TFA, UV 210 nm). After a water quench and phase separation, the organic layer is solvent-swapped into isopropanol. Crystallization as the dihydrochloride salt is initiated by controlled addition of 37% HCl, resulting in a crystalline monohydrate with a melting endotherm at 288–290 °C by DSC. Residual solvent limits are governed by ICH Q3C: dichloromethane 600 ppm, isopropanol 5000 ppm. The terminal product is micronized to a D₉₀ of 20 µm using a jet mill under nitrogen to maintain the ≥99.7% peak purity specified in the USP monograph.

Resolution with L-(+)-tartaric acid defines optical purity above 99.0% ee

Racemic 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole is resolved through diastereomeric salt formation with L-(+)-tartaric acid in a methanol/water (85:15 v/v) solvent system. A 1.0-equivalent charge of the chiral acid relative to the racemic diamine base precipitates the less soluble (S)-diamine L-tartrate salt. The slurry is heated to 60 °C until full dissolution, then cooled linearly at 0.3 °C/min to 5 °C to maximize crystal yield and enantiopurity. The collected salt is re-slurried twice in anhydrous ethanol at 50 °C to eject co-precipitated (R)-isomer; optical purity is verified by chiral HPLC using a Chiralpak AD-H column (250×4.6 mm, hexane/ethanol/diethylamine 80:20:0.1, flow 1.0 mL/min, UV 254 nm). The free base is liberated by neutralization with 2 N aqueous sodium hydroxide to pH 10.5–11.0, extracted into ethyl acetate, and concentrated to a viscous oil. A final short-path distillation at 150 °C and 0.1 mbar yields the (S)-diamine with a chemical purity exceeding 99.5% and an enantiomeric excess above 99.0%. The product is stored under argon at 2–8 °C to prevent oxidative discoloration; exposure to atmospheric carbon dioxide slowly forms a carbamate impurity detectable at RRT 1.18 in the USP method. This resolution step is mandatory before any pharmaceutical-grade downstream processing because the (R)-antipode gives an inactive dopamine receptor ligand.

The extended-release matrix tablet containing pramipexole dihydrochloride monohydrate is manufactured by aqueous wet granulation of a hydrophilic polymer network. Hypromellose (HPMC) type 2208 (viscosity 100,000 mPa·s) is used at a drug-to-polymer weight ratio of 1:160 for the 0.375 mg and 0.75 mg dose strengths, with the ratio adjusted to 1:120 for the 1.5 mg and 3 mg strengths to preserve a 24-hour zero-order release profile. The granulation endpoint is determined by a torque value of 15 N·m on the high-shear mixer (Gral 10 L bowl). After tray drying at 55 °C to a loss-on-drying of 1.5–2.5%, the granulate is milled through a 0.8 mm conidur screen and blended with extragranular HPMC K4M and colloidal silicon dioxide (0.15% w/w). Compression on a tablet press with 9 mm round standard concave tooling targets a hardness of 80–120 N; friability is held below 0.8% after 100 rotations in accordance with USP <1216>. The critical dissolution specification is Q=30–55% at 2 hours and Q≥75% at 12 hours in pH 6.8 phosphate buffer, paddle at 50 rpm. Process control includes NIR monitoring of tablet moisture content prior to packaging in high-density polyethylene bottles with desiccant canisters. Any deviation in HPMC substitution type—for example, substitution with HPMC 2910—accelerates release by 30–40% and must be avoided.

Quantitation of Process-Related Impurities Using USP Reference Standards Prepared from the Diamine Intermediate

When S-DATHB is available at a purity above 99.5%, it serves as a starting material for the synthesis of certified pharmacopoeial impurity standards such as Pramipexole Related Compound A (N-propyl sulfonamide analog) and Related Compound C (the (R)-enantiomer). A 100 mg aliquot of S-DATHB is reacted with 1.2 eq of propylsulfonyl chloride in dichloromethane at 0–5 °C with triethylamine scavenger to generate the sulfonamide impurity after 12 h. The crude material is purified by flash chromatography (silica gel, methanol/dichloromethane gradient) to ≥98.0% area purity as verified against the USP LC method and secondary qualification by ¹H‑NMR and high-resolution mass spectrometry. The standard is stored in amber vials at −20 °C under nitrogen and is qualified in a stability-indicating HPLC method per ICH Q2(R1) with quantitation limit 0.01% (signal-to-noise > 10:1). Each ampoule is accompanied by a certificate of analysis referencing ISO 17034 accreditation. The residual S-DATHB content in the impurity standard is controlled below 0.15% to prevent interference in spiked recovery experiments. Routine use of such reference materials in the QC release of pramipexole API tablets ensures that the total unspecified impurities do not exceed 0.10% as mandated by ICH Q3B(R2).

In central nervous system (CNS) medicinal chemistry, the (S)-2,6-diamino scaffold serves as a versatile chiral synthon beyond pramipexole. Structure–activity relationship programs with dopamine D₃ receptor partial agonists require a series of N-6 substituted tetrahydrobenzothiazoles. The optically pure S-DATHB is coupled with diverse carboxylic acids via HATU-mediated amidation in dimethylformamide at 0.2 M. Reaction completion is monitored by UPLC–MS (Acquity BEH C18, 1.7 µm, gradient acetonitrile/0.1% formic acid). After aqueous workup, the crude library compounds are purified on a preparative HPLC–MS system to >95% purity. The binding affinity at human D₃ receptors is determined using [³H]-spiperone competition binding assays; compounds with Ki below 10 nM are advanced to microdialysis studies in rodent striatum. The enantiomeric integrity of the building block is the decisive factor: a 1% contamination with the (R)-isomer reduces functional selectivity by over 60% in GTPγS assays. All laboratory operations adhere to the general safety provisions of REACH (EC) No 1907/2006 for the supply of research chemicals. The building block is typically supplied in septum-sealed glass bottles under argon, with a declaration of enantiomeric excess confirmed by the same Chiralpak AD-H method used in the production environment.